DNA WeCheck
天資基因檢測中心

COVID-19 Nucleic Acid (RNA) Screening Report
新型冠狀病毒核酸分子篩查報告

Name of Examinee: **檢測者姓名:**		**Specimen ID:** **樣本編號:**	
Date of Birth: **出生日期:**		**Specimen Type:** **樣本類別:**	
Gender/Age: **性別/年齡:**	/2026	**Collection Date & Time:** **採集日期及時間:**	
ID/Travel Document No.: **身份證/旅遊證件號碼:**		**Lab Received Date & Time:** **化驗所收取日期及時間:**	
Telephone Number: **電話號碼:**		**Report Date & Time:** **報告日期及時間:**	
Referring Doctor: **轉介醫生:**			

Test Item 檢測項目	Test Result 檢測結果	Reference Value 參考值
SARS-CoV-2 (COVID-19) Screen 新型冠狀病毒篩查		Not Detected 陰性
SARS-CoV-2 (COVID-19) PCR Ct value 新型冠狀病毒核酸 Ct 值		>40 See Remarks

Loo Tjing Yung PhD, MLT-Part 1
Registration No.: MT102375

DNA WeCheck Limited
天資基因檢測中心有限公司

Remarks 備註:

1. The specimen has been tested by Reverse Transcription PCR (RT-PCR) technology. Our detection kits detect the N gene and/or ORF1ab gene in the COVID -19 (SARS-CoV-2) virus. Qualitative detection of positive results does not indicate the presence of the live virus. Other detection methods can be used for confirmation at the same time. This test only classifies and identifies the new coronavirus COVID-19 (formerly known as 2019-nCoV). The clinical diagnosis and treatment of patients should be combined with their symptoms/signs, medical history, other laboratory tests and treatment responses considering. Although this test was designed to select relatively conservative fragments for amplification and detection, in theory, the missed detection of coronavirus types with rare mutations in the conserved regions is still possible.
   樣本以反轉錄聚合酶鏈式反應（RT-PCR）技術進行檢測。本公司所用試劑是以 2019 冠狀病毒(SARS-COV-2) 病毒的N 基因及/或ORF1ab 基因為檢測目標。定性檢測的陽性結果並不一定代表活性病 毒的存在。可考慮以其他檢測方法確認結果。 本次檢測僅對新型冠狀病毒 2019 冠狀病毒（前稱 2019-nCoV）進行分類及辨認。患者的臨床診斷及治療應視乎其症狀 / 病徵、病史、其他檢測結果及所考慮的治療反應而定。儘管本次檢測旨在選擇相對保守的片段作擴增及檢測，但理論上， 在保守區域中出現罕見基因突變的冠狀病毒類型仍可能會導致漏檢。

2. Reference Ct value is based on the interpretative instructions from Hai Kang Life Corporation Limited, "C/Tech SARS-CoV-2 RT-PCR Technology; Cat. No. C02-01-1180-100. Instructions for use for one step real time reverse transcription PCR for use of detection of SARS-COV2. The upper Ct limit is ≥40.
參考 Ct 值基於海康生命科技有限公司 "C/Tech SARS-CoV-2 RT-PCR 技術； 目錄號 C02-01-1180-100。 用於檢測SARS-COV2 的使用說明。Ct 值上限≥40。
3. The test result should not be used as the sole basis for medical diagnosis, and a "Not Detected" result cannot completely rule out infection of COVID-19. The test result should be interpreted with other clinical and diagnostic information. A false negative may occur if a specimen is improperly collected, transported or handled. It is a possibility that you may have been exposed to the COVID- 19 Virus after your sample was collected. The possibility of a false negative result should especially be considered if the patient's recent exposures or clinical presentation suggest that COVID-19 infection is possible. If COVID-19 infection is still suspected, re-testing should be considered in consultation with public health authorities. This test cannot rule out diseases caused by other bacterial or viral pathogens. A negative result does not at any time preclude the possibility of COVID-19 infection.
檢測結果不應作為醫學診斷的唯一依據，陰性結果並不能完全排除新型冠狀病毒感染。 檢測結果應結合其他臨床和診斷 資訊一併演繹。樣本收集、運送或處理不當，均有機會令檢測結果呈假陰性。閣下亦可能在收集樣本後接觸到 2019 冠狀 病毒。如果患者最近的行踪或臨床表現顯示有可能感染 2019 冠狀病毒，則應特別注意假陰性結果的可能性。如仍懷疑受 2019 冠狀病毒感染，應向公共衛生當局諮商以決定是否需要再作檢測。本次檢測不能排除由其他細菌或病毒病原體引起 的疾病。在任何時候，陰性結果均不會排除感染 2019 冠狀病毒的可能性。
4. This report does not constitute legal, health, safety, or medical advice and is not a recommendation of any action or non-action. DWC is not responsible or liable for any injuries caused during the sample collection procedure. In no circumstances whatsoever shall DWC be liable for any indirect, consequential, special or incidental damages arising out of or in connection with this report. Once payment has been submitted with the test request form, there shall be no refunds in any circumstances.
本報告不構成法律、健康、安全或醫學意見，亦非對採取或不採取任何行動的建議。DWC 對樣本收集過程中所造成的任何 人身傷害概不負責。在任何情況下，本報告引起或與之相關的任何間接、相應而生、特殊或附帶的損害，DWC 概不負責。 在任何情況下，款項及檢測申請表一經提交，將不獲退款。